This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

capsaicin (Qutenza®)

Reference No. 823

Publication date:

Last review date:

Appraisal information

capsaicin (Qutenza®) 179 mg cutaneous patch

Company: Astellas Pharma Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 04/01/2012
AWMSG meeting date: 08/02/2012
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0412
Ratification by Welsh Government: 08/03/2012

Current Progress

Ratification by
Welsh Government

AWMSG advice

Capsaicin patch (Qutenza®) is not recommended for use alone for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults. Capsaicin patch (Qutenza®) is recommended as an option for restricted use within NHS Wales for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults in combination with other medicinal products for pain and in patients who have not received adequate benefit from, or are intolerant to, alternative conventional treatments. The company submission provided evidence on the cost effectiveness of capsaicin patch (Qutenza®) as an add-on treatment in patients who were refractory to or intolerant of usual first or second line treatments. Capsaicin patches (Qutenza®) should be administered by healthcare professionals who have completed the approved training and in a specialist clinic setting. AWMSG is of the opinion that capsaicin patch (Qutenza®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary